Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NRG Oncology
NRG Oncology
NRG Oncology
Eastern Cooperative Oncology Group
Emory University
Emory University
Mayo Clinic
Emory University
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC